Autolus Therapeutics Income Statement (2017-2025) | AUTL

Income Statement Sep2017 Dec2017 Sep2018 Dec2018 Dec2019 Dec2020 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
3.83M1.29M0.41M10.10M0.03M8.98M20.92M21.19M24.29M
Cost of Revenue (Quarter)
11.39M17.95M24.45M28.64M25.33M
Gross Profit (Quarter)
10.10M-11.36M-8.97M-3.52M-7.45M-1.04M
Operating items
Research & Development (Quarter)
28.36M30.79M31.48M7.55M27.39M33.23M32.32M37.54M30.67M36.61M40.32M30.83M26.73M27.43M27.89M35.63M
Selling, General & Administrative (Quarter)
7.99M8.27M8.23M7.41M9.28M11.12M10.61M15.73M18.18M21.90M27.33M34.31M29.53M30.27M36.28M35.80M
Other Operating Expenses (Quarter)
-0.52M-3.77M-0.02M-0.22M-0.00M25.33M
Operating Expenses (Quarter)
36.35M39.06M39.72M14.96M36.67M44.35M42.93M53.27M48.85M58.93M67.88M75.89M74.22M82.14M92.81M96.75M
Operating Income (Quarter)
-36.19M-39.06M-37.35M-11.65M-39.15M-44.38M-42.91M-53.27M-38.76M-58.93M-67.88M-75.86M-65.24M-61.22M-71.62M-72.47M
EBIT (Quarter)
-36.19M-39.06M-37.35M-11.65M-39.15M-44.38M-42.91M-53.27M-38.76M-58.93M-67.88M-75.86M-65.24M-61.22M-71.62M-72.47M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.09M0.17M1.43M3.45M3.40M3.65M-10.49M6.93M9.66M8.32M32.35M6.14M5.23M0.09M18.52M
Other Non Operating Income (Quarter)
0.86M-1.33M-3.74M6.25M0.78M0.48M-1.70M3.04M-1.30M1.20M-11.88M11.40M0.13M1.50M-0.91M0.40M
Non Operating Income (Quarter)
-0.90M-3.05M-5.42M4.22M-0.68M-1.14M-2.96M-23.92M-13.94M0.71M-14.20M49.72M-2.70M13.70M-6.96M-19.05M
Net income details
EBT (Quarter)
-37.09M-42.12M-42.77M-7.43M-39.83M-45.51M-45.87M-77.19M-52.70M-58.22M-82.07M-26.14M-67.94M-47.52M-78.59M-91.52M
Tax Provisions (Quarter)
-0.03M-0.06M-0.01M19.55M-0.01M0.04M-0.02M-0.02M-0.01M0.05M0.02M1.46M2.23M0.40M0.53M-1.18M
Profit After Tax (Quarter)
-37.06M-42.06M-42.77M-26.95M-39.81M-45.60M-51.69M-77.20M-52.69M-58.27M27.01M164.78M-70.16M18.97M-84.90M-66.51M
Income from Continuing Operations (Quarter)
-37.06M-42.06M-42.77M-26.98M-39.81M-45.55M-45.85M-77.17M-52.69M-58.27M-82.09M-27.61M-70.16M-47.92M-79.12M-90.33M
Consolidated Net Income (Quarter)
-37.06M-42.06M-42.77M-26.98M-39.81M-45.55M-45.85M-77.17M-52.69M-58.27M-82.09M-27.61M-70.16M-47.92M-79.12M-90.33M
Income towards Parent Company (Quarter)
-37.06M-42.06M-42.77M-26.98M-39.81M-45.55M-45.85M-77.17M-52.69M-58.27M-82.09M-27.61M-70.16M-47.92M-79.12M-90.33M
Net Income towards Common Stockholders (Quarter)
-37.06M-42.06M-42.77M-26.98M-39.81M-45.55M-45.85M-77.17M-52.69M-58.27M-82.09M-27.61M-70.16M-47.92M-79.12M-90.33M
Additional items
EPS (Basic) (Quarter)
-0.41-0.46-0.47-0.28-0.23-0.26-0.26-0.44-0.24-0.22-0.31-0.11-0.26-0.18-0.30-0.34
EPS (Diluted) (Quarter)
-0.41-0.46-0.47-0.28-0.23-0.26-0.26-0.44-0.24-0.22-0.31-0.11-0.26-0.18-0.30-0.34
Shares Outstanding (Quarter)
39.37M43.07M51.56M72.08M90.91M90.93M91.24M94.99M173.83M173.86M173.98M173.94M222.17M266.03M266.08M255.16M266.13M266.14M266.14M266.14M
Shares Outstanding (Diluted) (Quarter)
43.07M51.56M72.08M90.91M90.93M91.24M94.99M173.83M173.86M173.98M173.94M222.17M266.03M266.08M255.16M266.13M266.14M266.14M266.14M
EBITDA (Quarter)
-36.19M-39.06M-37.35M-11.65M-39.15M-44.38M-42.91M-53.27M-38.76M-58.93M-67.88M-75.86M-65.24M-61.22M-71.62M-72.47M
Interest Expenses (Quarter)
2.87M11.87M4.26M85.50M1.79M1.81M1.85M3.46M4.91M5.02M5.01M30.13M19.27M10.17M10.69M-30.84M110.97M119.82M10.52M22.84M
Tax Rate (Quarter)
0.07%0.13%0.01%-263.16%0.04%-0.09%0.05%0.03%0.02%-0.09%-0.03%-5.59%-3.28%-0.84%-0.68%1.29%